Investigation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of NNC0581-0001 in Participants With Hepatic Steatosis and Suspected Steatohepatitis
Latest Information Update: 26 Mar 2025
At a glance
- Drugs NNC-0581-0001 (Primary)
- Indications Fatty liver; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 26 Mar 2025 New trial record